These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 27151934

  • 1. Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.
    Hong N, Shen Y, Yu CY, Wang SQ, Tong JP.
    Acta Ophthalmol; 2016 Jun; 94(4):334-45. PubMed ID: 27151934
    [Abstract] [Full Text] [Related]

  • 2. Association of the Complement Factor H Y402H Polymorphism and Response to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration: An Updated Meta-Analysis.
    Roshanshad A, Moosavi SA, Arevalo JF.
    Ophthalmic Res; 2024 Jun; 67(1):358-386. PubMed ID: 38754401
    [Abstract] [Full Text] [Related]

  • 3. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
    Kubicka-Trząska A, Karska-Basta I, Kobylarz J, Dziedzina S, Sanak M, Romanowska-Dixon B.
    Klin Oczna; 2016 Jun; 118(2):114-21. PubMed ID: 29912491
    [Abstract] [Full Text] [Related]

  • 4. Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.
    Chen G, Tzekov R, Li W, Jiang F, Mao S, Tong Y.
    Sci Rep; 2015 Sep 28; 5():14517. PubMed ID: 26411831
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
    Mohamad NA, Ramachandran V, Ismail P, Mohd Isa H, Chan YM, Ngah NF, Md Bakri N, Ching SM, Hoo FK, Wan Sulaiman WA, Inche Mat LN, Hazmi Mohamed M.
    Bosn J Basic Med Sci; 2018 Aug 01; 18(3):260-267. PubMed ID: 29579408
    [Abstract] [Full Text] [Related]

  • 7. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.
    Brantley MA, Fang AM, King JM, Tewari A, Kymes SM, Shiels A.
    Ophthalmology; 2007 Dec 01; 114(12):2168-73. PubMed ID: 18054635
    [Abstract] [Full Text] [Related]

  • 8. Genetic Variants of Complement Factor H Y402H (rs1061170), C2 R102G (rs2230199), and C3 E318D (rs9332739) and Response to Intravitreal Anti-VEGF Treatment in Patients with Exudative Age-Related Macular Degeneration.
    Kubicka-Trząska A, Żuber-Łaskawiec K, Dziedzina S, Sanak M, Romanowska-Dixon B, Karska-Basta I.
    Medicina (Kaunas); 2022 May 13; 58(5):. PubMed ID: 35630075
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Investigation of genetic base in the treatment of age-related macular degeneration.
    Gourgouli K, Gourgouli I, Tsaousis G, Spai S, Niskopoulou M, Efthimiopoulos S, Lamnissou K.
    Int Ophthalmol; 2020 Apr 13; 40(4):985-997. PubMed ID: 31916060
    [Abstract] [Full Text] [Related]

  • 13. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.
    Orlin A, Hadley D, Chang W, Ho AC, Brown G, Kaiser RS, Regillo CD, Godshalk AN, Lier A, Kaderli B, Stambolian D.
    Retina; 2012 Jan 13; 32(1):4-9. PubMed ID: 21878851
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kawashima Y, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ueda-Arakawa N, Yoshikawa M, Takahashi A, Yoshimura N.
    Graefes Arch Clin Exp Ophthalmol; 2015 Sep 13; 253(9):1471-7. PubMed ID: 25391986
    [Abstract] [Full Text] [Related]

  • 18. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Nischler C, Oberkofler H, Ortner C, Paikl D, Riha W, Lang N, Patsch W, Egger SF.
    Acta Ophthalmol; 2011 Jun 13; 89(4):e344-9. PubMed ID: 21232084
    [Abstract] [Full Text] [Related]

  • 19. CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in Exudative Age-Related Macular Degeneration.
    Kepez Yildiz B, Ozdek S, Ergun MA, Ergun S, Yaylacioglu Tuncay F, Elbeg S.
    Ophthalmic Res; 2016 Jun 13; 56(3):132-8. PubMed ID: 27404493
    [Abstract] [Full Text] [Related]

  • 20. Association of risk genotypes of ARMS2/LOC387715 A69S and CFH Y402H with age-related macular degeneration with and without reticular pseudodrusen: a meta-analysis.
    Jabbarpoor Bonyadi MH, Yaseri M, Nikkhah H, Bonyadi M, Soheilian M.
    Acta Ophthalmol; 2018 Mar 13; 96(2):e105-e110. PubMed ID: 28593728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.